ApiotiX Technologies’ Post

𝗙𝗼𝗿𝘄𝗮𝗿𝗱 𝗧𝗼𝘄𝗮𝗿𝗱 🚀 "𝗘𝗮𝗰𝗵 𝗻𝗲𝘄 𝘄𝗲𝗲𝗸 𝗶𝘀 𝗮 𝗻𝗲𝘄 𝗼𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝘆 𝗳𝗼𝗿 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻. 𝗟𝗲𝘁’𝘀 𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗲 𝗮𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝘁𝗼𝗴𝗲𝘁𝗵𝗲𝗿!" In clinical research, progress never takes a day off. Each Monday is a fresh start, a new chance to push boundaries, ask the right questions, and create a meaningful impact. Whether refining trial designs, managing complex global studies, or sourcing strategic R&D services, every innovation brings us closer to breakthroughs. From offering customized project solutions to conducting clinical evaluations for cutting-edge medical devices, diagnostics, and digital therapeutics, our work is all about making an impact. Let’s dive into this week with renewed energy and commitment to driving innovations that can transform lives! #ClinicalResearch #Innovation #NewWeekNewOpportunities

🌟 Gemina Labs is at the forefront of biosensing and diagnostics, specializing in designing, building, and distributing point-of-care diagnostic solutions for respiratory ailments, empowered by their groundbreaking proprietary chemistry. CEO Brian Firth explains that this chemistry, heralded as one of the most significant advancements in rapid in vitro diagnostics, not only enhances product efficiency but also reduces production costs while improving accuracy. By extending its application to other producers' lateral flow technologies, Gemina Labs is driving progress towards the global availability of affordable, rapid, and lab-accurate point-of-care diagnostics in any setting.🔬🧬🦠 Looking ahead, Brian Firth shares that the company anticipates significant milestones, including commercial license announcements and technology expansions, reflecting a strategic roadmap for revenue growth and innovation. Gemina's commitment to advancing diagnostics while simultaneously pursuing revenue opportunities underscores its potential to save lives and drive substantial industry-wide cost savings, positioning it as a key player in the evolving landscape of healthcare diagnostics.🌎 Watch Brian Firth's update 🔗 https://lnkd.in/eURtdmrR #pointofcarediagnostics #innovation #medtech #vitrodiagnostics #healthcare

A tale of two medtech cities! Jami Marsh and I had a blast talking about how great our respective cities are in this space - MSP edging out Salt Lake City :). Both are powerhouses for different reasons, and JLL's 2023 Life Sciences Report highlighted the top 5 cities for medtech, highlighting different segments of the Life Science world that we happen to lead in. @jll @lifesciencerealestate

The #lifesciences industry is more than just the research and development of new therapeutics. Medical devices and technology play a critical role in these scientific endeavors. In JLL's newly released Life Sciences and #RealEstate Perspective, Minneapolis and Salt Lake City are highlighted as two of the top 5 thriving #medtech markets. JLL experts Jami Marsh and Jessica Mogilka discuss what's driving the growth in each of their respective cities in our new CRE Insider episode. Download the full report for more: https://co.jll/42VgkY2

BioWorld ’s Shani Alexander spoke with Antoine Papiernik, Sofinnova Partners’ Chairman and Managing Partner, on why this is such a promising time for the #medtech sector. Antoine discussed what it takes to build a successful medtech company, offering recent examples, such as Shockwave Medical, LimFlow SA, Pi-Cardia, HighLife, Moon Surgical and RefleXion Medical. He also highlighted what it takes to attract investor interest, demonstrating that the technology can transform a specific indication and significantly impact patients. Finally, bringing a product to market and achieving a successful exit takes time—Shockwave Medical, for example, took 12 years to become a billion-dollar company. 🔗Learn more: https://lnkd.in/eCpZJ-Ep

With the aim of driving investment outcomes, #AusMedtechInvest 2024 features presentations from 8 private and listed Australian medtechs, spanning early to late-stage, seeking partners to further commercialise their technology. Wellumio is great to be part of the #AusMedtechInvest and on the podium today! #AusBioInv #biggestweekinmedtech #AusMedtechInvest2024

Recently, we launched our redesigned website and refreshed brand, showcasing not just a new look, but a renewed commitment to driving success in drug development and commercialization, and improving patient outcomes. ✍️ In our latest blog, Sofie Vandevyver, PhD, Vice President and Global Head of Marketing at Cytel, explains the reasons behind our transformation and the core elements of our new brand. And that's not all! 💡Sofie dives into the hottest industry trends and reveals how we are uniquely positioned to help you unlock the full potential of therapies. Read the full article: https://bit.ly/4cxJIaE #DataScience #DrugDevelopment #NewCytel #Transformation #PatientOutcomes

check out the blog post by my colleague Sofie Vandevyver, PhD about the journey behind our new brand and graphic identity!

Excited to share this article by Tanya Kogan, Product Lead at Greenphire and Kim Boericke, COO at THREAD: "Driving diversity in clinical research: The positive impact of technology-enabled trials in ensuring equal representation for all.” Diversity in clinical research is crucial to ensure that treatments are effective and safe for everyone. Learn how the power of technology is enabling trials to address the barriers to participation, making clinical studies more accessible for everyone, everywhere. Read the full article > https://lnkd.in/ehCfds-7 #ClinicalTrialsDiversity #TechnologyEnabledTrials #InclusiveTrials

Last week, I had the profound privilege of visiting the headquarters of ROKIT Healthcare in Seoul. Reflecting on our journey over the past three years since DRADS Capital’s round-leading investment, I am filled with immense pride in what we have accomplished together. Since this investment, ROKIT Healthcare has achieved a plethora of noteworthy milestones, including securing FDA and European approvals, successfully completing clinical trials, and achieving commercialization in over 30 countries. These accomplishments speak volumes about ROKIT’s commitment to innovation and excellence in the medical devices sector. A particular highlight of ROKIT’s achievements is the 2A rating awarded by the KOSDAQ Technical Evaluation Assessment Agency, a testament to their technological innovation and market potential. Moreover, the CE approvals for commercialization in European countries underscore the quality and safety of their products. The European Medical Agency's classification of their device as a "class IIa" medical device reflects rigorous evaluation and compliance with the highest standards. Central to ROKIT's achievements is the visionary leadership of Chairman SeokHwan. You. His foresight and dedication have not only cultivated a culture of innovation but also steered the company through groundbreaking advancements, demonstrating the transformative impact of exceptional leadership in the healthcare industry. As we look forward, ROKIT’s trajectory is a compelling example of how innovative technology can address complex healthcare challenges worldwide. DRADS Capital is proud to be part of this journey — contributing to a future where healthcare is enhanced by technology. JEEHEE KIM, PH.D, Kenneth Chan, Aram T. Salzman, Shaun Patel, Shamini Ramanujan, Archana Nagarajan, Divyesh Nagarajan, #biotechnology, #lifesciences, #genomics, #antiaging, #regeneration, #KOSDAQ, #Korean, #government, #Seoul, #Harvard, #regeneration, #kidney, #healthcare